AbCellera Biologics Inc. Common Shares Study result
Review the key takeaways and the transcript of this earnings call.
- AbCellera reported top line four-week phase two data for a BCL635 in treating moderate to severe hot flashes, showing efficacy beyond their target product profile and strong differentiation versus approved NK3R competitors in efficacy, safety, and dosing convenience.
- The study enrolled 92 postmenopausal patients randomized 1:1 to a single 600 mg subcutaneous dose of a BCL635 or placebo, with efficacy assessed primarily at four weeks.
- A BCL635 reduced moderate or severe vasomotor symptom (VMS) events by 8.8 per day versus 3.5 for placebo, a placebo-adjusted difference of 5.3 events, representing an 83% reduction from baseline versus 33% for placebo.
- Severity scores decreased by 1.4 points versus 0.3 for placebo, a placebo-adjusted difference of 1.1 points, with 37% of treated patients achieving complete resolution of moderate or severe VMS events compared to 2.2% for placebo.
- Sleep disturbance improved by 9 points on the PROMIS scale versus 3.5 for placebo, with benefits across multiple sleep domains.
- Patient Global Impression of Change showed 71% of a BCL635 patients reported symptoms as much better at four weeks versus 16% for placebo.
- Safety data showed no serious or severe adverse events in the a BCL635 group; common adverse events included mild, transient headaches and fatigue, with no gastrointestinal toxicity and minimal liver enzyme elevations resolving without intervention.
- The data quality was high with 98.5% diary compliance, and the study population had a higher mean age and slightly lower baseline VMS frequency compared to registrational studies of approved small molecules.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first five paragraphs, organized by speaker.
Good afternoon, and welcome to the ABCL635 phase II clinical update. My name is Jonathan, and I will facilitate the audio portion of today's interactive broadcast. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. At this time, I would like to turn the call over to Tryn Stimart, Chief Legal and Compliance Officer.
You may proceed. Good morning, good afternoon, and good evening, everyone.
I am Tryn Stimart, AbCellera's Chief Legal and Compliance Officer. We are pleased to welcome you to AbCellera's conference call to discuss our phase II top-line data for ABCL-635. Speaking on the call today are Carl Hansen, AbCellera's President and Chief Executive Officer, Sarah Noonberg, AbCellera's Chief Medical Officer, and Dr. Kelsey Mills, an obstetrician and gynecologist specializing in complex menopause care. During this call, we may make forward-looking statements based on our current expectations and in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include statements regarding the therapeutic potential, safety profile, and regulatory pathway for ABCL-635. Our statements are subject to a number of risks, uncertainties, and other factors that could cause actual results to differ materially from those described.
Please review the Risk Factors section of our most recent Form 10-K and subsequent 10-Q filings with the SEC for a more detailed discussion of these risks. AbCellera assumes no obligations to update any forward-looking statements to reflect events or circumstances after today's date. Our presentation today, our press release, and our SEC filings are available on our investor relations website. The information we provide about ABCL-635 is intended for the investment community and is not promotional. As we transition to our prepared remarks, please note that this call is being recorded and will be available for replay on our investor relations website. After our prepared remarks, we will open the lines for questions and answers. With that, I will turn the call over to Carl.
Thanks, Tryn, and good morning, everyone. I have to say that we are more than excited to share our top-line 4-week data for the phase II study of ABCL635 in the treatment of moderate to severe hot flashes. As I said on last week's earnings call, coming into this readout, we were defining success as comparable efficacy to small molecules, improved safety profile that eliminated the need for liver monitoring, and a more convenient once-monthly self-injection dosing regimen. With this product profile, we believed ABCL635 had potential to be a blockbuster product. The top-line results, which were released this morning, exceed our target product profile, and the efficacy data is beyond even the most aggressive upside scenario we had dared to consider.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
12 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring